Abstract

2019 Novel Coronavirus Disease (COVID-19) in Patients With Inflammatory Bowel Diseases

Aliment Pharmacol Ther. 2020 May 2. doi: 10.1111/apt.15804. Online ahead of print.

Carlos Taxonera 1, Iñigo Sagastagoitia 2, Cristina Alba 1, Norberto Mañas 1, David Olivares 1, Enrique Rey 1

 
     

Author information

1Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos [IdISSC], Madrid, Spain.

2Department of Internal Medicine, Hospital Clínico San Carlos and Instituto de Investigación del Hospital Clínico San Carlos [IdISSC], Madrid, Spain.

Abstract

Background: Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS-CoV-2) disease (COVID-19) are lacking.

Aim: To report the clinical characteristics, including gastrointestinal symptoms, of COVID-19 in IBD patients, and to assess the risk of COVID-19 in IBD.

Methods: This case series included consecutive IBD patients with laboratory-confirmed COVID-19. Age-adjusted cumulative incidences were compared with the general population in the Madrid region.

Results: Through April 8, 12 patients of 1918 IBD patients were diagnosed of COVID-19. The average age was 52 years, 75% of the patients were female, and 58.3% had Crohn's disease. Seven patients (58%) were on maintenance treatment with immunomodulators/biologics, of these 4 with combined therapy (33%). Eight patients (66%) required hospitalization (1 intensive care unit admission, and 2 deaths), and 4 patients were isolated at home. Nine patients had diarrhoea ranging between 4-10 loose stools per day (mean 5.4, SD 1.6). In 5 patients (42%) diarrhoea was a presenting symptom. In 2 patients, diarrhoea was the only symptom at debut. Cumulative incidence of COVID-19 was 6.1 per 1000 IBD patients. IBD patients had a lower adjusted incidence ratio of COVID-19 (OR 0.74, 95% CI 0.70-0.77; p<0.001), and a similar associated mortality ratio (OR 0.95, 95% CI: 0.84-1.06; p=0.36), compared with the general population.

Conclusions: IBD patients do not have an increased risk of COVID-19 and associated mortality compared with the general population. In many IBD patients diarrhoea was a presenting symptom, and sometimes, was the only symptom at onset of COVID-19.

© Copyright 2013-2020 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.